No black box warning on record for Odefsey

As of the latest FDA labeling reviewed, Odefsey (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Odefsey medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Skin and Hypersensitivity Reactions: Severe skin and hypersensitivity reactions have been reported during postmarketing experience with RPV-containing regimens, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Immediately discontinue treatment if hypersensitivity or rash with systemic symptoms or elevations in hepatic serum biochemistries

No black box warning on record for Odefsey

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Skin and Hypersensitivity Reactions: Severe skin and hypersensitivity reactions have been reported during postmarketing experience with RPV-containing regimens, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Immediately discontinue treatment if hypersensitivity or rash with systemic symptoms or elevations in hepatic serum biochemistries

Odefsey Black Box Warning

No black box warning on record for Odefsey

Other warnings & precautions

Odefsey Black Box Warning

No black box warning on record for Odefsey

Other warnings & precautions